Rehovot, Israel

Danny Frumkin

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 14(Granted Patents)


Location History:

  • Tel Aviv, IL (2016)
  • Rehovot, IL (2016 - 2024)

Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Danny Frumkin

Introduction

Danny Frumkin is a notable inventor based in Rehovot, Israel. He has made significant contributions to the field of biomedical technology, particularly in the area of blood analysis. With a total of 10 patents to his name, Frumkin's work has advanced the methods used in medical diagnostics.

Latest Patents

Frumkin's latest patents include innovative methods and kits for determining the efficiency of plasma separation from whole blood. These methods utilize real-time PCR amplification of two distinct amplicons, allowing for precise measurement of separation efficiency based on the differences in amplification patterns. Additionally, he has developed methods and systems for detecting methylation changes in DNA samples. This technology is particularly useful for analyzing DNA obtained from biological fluids such as plasma and urine, providing highly sensitive detection capabilities.

Career Highlights

Throughout his career, Danny Frumkin has been associated with Nucleix, a company that focuses on developing cutting-edge diagnostic solutions. His work has not only contributed to the advancement of medical technology but has also positioned Nucleix as a leader in the field.

Collaborations

Frumkin has collaborated with talented individuals such as Adam Wasserstrom and Revital Knirsh, further enhancing the innovative environment at Nucleix.

Conclusion

Danny Frumkin's contributions to the field of biomedical technology through his patents and work at Nucleix highlight his role as a significant inventor. His innovative methods for blood analysis and DNA detection continue to impact the medical diagnostics landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…